Silva, Saulo Brito; Wanderley, Carlos Wagner Souza; Marin, José Flavio Gomes; Macedo, Mariana Petaccia de; Nascimento, Ellen Caroline Toledo do; Antonacio, Fernanda Fronzoni; Figueiredo, Caroline Sales; Cunha, Mateus Trinconi 
; Cunha, Fernando de Queiroz ; Castro Junior, Gilberto de
Fonte: Therapeutic Advances in Medical Oncology. Unidades: FMRP, FM
Assuntos: BIOMARCADORES, GLICOSE, IMUNOTERAPIA, NEOPLASIAS PULMONARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Saulo Brito et al. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, v. 14, p. 1-13, 2022Tradução . . Disponível em: https://doi.org/10.1177/17588359221138386. Acesso em: 23 jun. 2024.APA
Silva, S. B., Wanderley, C. W. S., Marin, J. F. G., Macedo, M. P. de, Nascimento, E. C. T. do, Antonacio, F. F., et al. (2022). Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, 14, 1-13. doi:10.1177/17588359221138386NLM
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2024 jun. 23 ] Available from: https://doi.org/10.1177/17588359221138386Vancouver
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2024 jun. 23 ] Available from: https://doi.org/10.1177/17588359221138386
